Stockscreener 앱 받기
0.00
100.00%
-16.91
시간 외 거래:
16.60
16.60
+
전일 마감가:
$16.91
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$408.69M
수익:
$1.70M
순이익/손실:
$-47.01M
주가수익비율:
0.00
EPS:
-1.7
순현금흐름:
$-157.28M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$17.17
52주 변동 폭
$0.00
$23.35
Puretech Health Plc Adr Stock (PRTC) Company Profile
PRTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTC
Puretech Health Plc Adr
|
0.00 | 408.69M | 1.70M | -47.01M | -157.28M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Puretech Health Plc Adr Stock (PRTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
Puretech Health Plc Adr 주식(PRTC)의 최신 뉴스
PureTech Health (NASDAQ:PRTC) Trading 0.4% HigherStill a Buy? - MarketBeat
PureTech Health (NASDAQ:PRTC) Stock Price Up 3.1%Time to Buy? - MarketBeat
PureTech Health PLC Sponsored ADR $PRTC Shares Sold by Birch Hill Investment Advisors LLC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 100.0% in September - MarketBeat
Free cash flow per share of PureTech Health PLC Sponsored ADR – NASDAQ:PRTC - TradingView
PureTech Health (NASDAQ:PRTC) Trading Up 3.6%Here's What Happened - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Significant Growth in Short Interest - MarketBeat
PureTech Health (LON:PRTC) Shares Up 14.2% – Should You Buy? - Defense World
PureTech Health Sees Strong Market Presence in FTSE All Share - Kalkine Media
Parallel Advisors LLC Acquires 1,718 Shares of GSK PLC Sponsored ADR $GSK - Defense World
What Makes PureTech Health (PRTC) a New Buy Stock - Yahoo Finance
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Large Growth in Short Interest - MarketBeat
BioHarvest Sciences (BHST) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
PureTech Health (NASDAQ:PRTC) Shares Up 4.7%Time to Buy? - MarketBeat
PureTech Health Cash Runway Extended - The Motley Fool
International Flavors & Fragrances (NYSE:IFF) & DAQO New Energy (NYSE:DQ) Critical Comparison - Defense World
Conference Calls and Individual Investors - MarketBeat
Deupirfenidone: A Potential New Standard of Care - Placera.se
PureTech launches new entity to advance IPF treatment deupirfenidone - Investing.com
PureTech Health to report half-yearly results on August 28 - Investing.com
PureTech Health to report half-yearly results on August 28 By Investing.com - Investing.com South Africa
PureTech Health (NASDAQ:PRTC) Trading Up 1.4% – Still a Buy? - Defense World
PureTech Health (NASDAQ:PRTC) Shares Down 7.3% – Here’s What Happened - Defense World
PureTech’s Seaport doses first patient in phase 2b depression study By Investing.com - Investing.com South Africa
PureTech Health names Robert Lyne as interim CEO as Chowrira departs - Investing.com
PureTech Health names Robert Lyne as interim CEO as Chowrira departs By Investing.com - Investing.com India
Big Oil's Q2 Outlook: Downstream Gains and Upstream Pains - The Globe and Mail
PureTech Health announces board leadership transition By Investing.com - Investing.com South Africa
PureTech Health announces board leadership transition - Investing.com
PureTech Health announces board chair Raju Kucherlapati steps down - Investing.com
PureTech Health issues shares to executives following RSU vesting - Investing.com
PureTech Health announces RSU vesting and share transactions by PDMR - Investing.com
Citius Oncology (CTOR) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
PureTech set for Jefferies Global Healthcare Conference chat - Investing.com
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial - Placera.se
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
PureTech Health to release annual financial results April 30 - Investing.com
PureTech Health enlists Peel Hunt as joint broker - Investing.com
Invesco Ltd: Form 8.3PureTech Health PLC; Opening Position disclosure - The Manila Times
Nordic Capital XI ends pursuit of PureTech acquisition - Investing.com
PureTech Health (LSE: PRTC) Presents Promising Phase 1b Data for LYT-200 in AML and MDS at ASH 2024 - Kalkine Media
India Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Argentina Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Norway Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Japan Anti-obesity Medication Market Size & Outlook, 2030 - Grand View Research
Mexico Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Asia Pacific Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Anti-obesity Medication Market Size & Outlook, 2030 - Grand View Research
Top Biotech Stocks: Exploring Innovation Opportunities - MarketBeat
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share - FinancialContent
symbol__ Stock Quote Price and Forecast - CNN
Puretech Health Plc Adr (PRTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):